×
About 48,862 results

Pre-diagnostic serum concentrations of organochlorines and risk of acute myeloid leukemia: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
https://www.sciencedirect.com/science/article/pii/S0160412018317562?via%3Dihub
Environment International; Bassig,B.,et al

Feb 1st, 2019 - BACKGROUND: Epidemiologic studies suggest an increased risk of leukemia among individuals occupationally exposed to some organochlorine (OC) compounds. Associations between serum OC pesticide and polychlorinated biphenyl (PCB) levels and risk of acute myeloid leukemia (AML), the most common subtype of acute leukemia in adult populations, have not been evaluated prospectively in the general popu...

Two decades of using the combination of tetracycline derivatives and niacinamide as ste...
https://doi.org/10.1016/j.jaad.2014.04.040
Journal of the American Academy of Dermatology; McCarty M, Fivenson D

Jun 7th, 2014 - The twin goals of long-term disease control and minimizing toxicities related to immunosuppression necessitate efforts to find effective steroid-sparing agents in the management of patients with autoimmune bullous diseases. Pemphigus especially requires a long view, because the disease can persist throughout a patient's lifetime, yet few clinical trial reports exist to guide the practitioner. W...

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary scle...
https://doi.org/10.1002/hep.27074
Hepatology (Baltimore, Md.); Wunsch E, Trottier J et. al.

Feb 12th, 2014 - Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10-15 mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, and fibroblast growth...

Autologous transplantation and maintenance therapy in multiple myeloma.
https://doi.org/10.1056/NEJMoa1402888
The New England Journal of Medicine; Palumbo A, Cavallo F et. al.

Sep 3rd, 2014 - This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed multiple myeloma. We randomly assigned 273 patients 65 years of age or younger to h...

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone...
https://doi.org/10.1200/JCO.2013.53.9593
Journal of Clinical Oncology : Official Journal of the Am... Crump M, Kuruvilla J et. al.

Sep 30th, 2014 - For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic than standard treatment. We randomly assigned 619 patients with relapsed/refractory aggressive lymphoma to treatment with gemcitabine, dexamethasone, and cisplatin (GDP) or to dexamethasone, cytarabine, ...

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associate...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455597
Journal of Clinical Oncology : Official Journal of the Am... Kochenderfer JN, Somerville RPT et. al.

Mar 15th, 2017 - Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new...

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of g...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482737
British Journal of Cancer; Hurt CN, Falk S et. al.

Apr 4th, 2017 - SCALOP, a randomised, phase II trial, tested the activity and safety of gemcitabine (GEM)-based and capecitabine (CAP)-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Here we present the long-term outcomes. Eligibility: histologically proven LAPC ⩽7 cm. Following 12 weeks of induction GEMCAP chemotherapy (three cycles: GEM 1000 mg m-2 days 1, 8, 15; CAP 830 mg m-2 days...

Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical P...
https://doi.org/10.1200/JCO.2017.72.4948
Journal of Clinical Oncology : Official Journal of the Am... Khorana AA, Mangu PB et. al.

Apr 11th, 2017 - Purpose To update the Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016. The October 2016 update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primar...

Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
https://doi.org/10.1056/NEJMoa1014460
The New England Journal of Medicine; Dooley MA, Jayne D et. al.

Nov 17th, 2011 - Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis. We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day), plus placebo in each grou...

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631139
The New England Journal of Medicine; Von Hoff DD, Ervin T et. al.

Oct 17th, 2013 - In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. We randomly assigned patients with a Karnofsky performance-status score of ...

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced...
https://doi.org/10.1002/cncr.24438
Cancer Figlin RA, de Souza P et. al.

Jun 15th, 2009 - Exploratory subgroup analyses from the phase 3 global advanced renal cell carcinoma (ARCC) trial were conducted to determine if baseline levels of the tumor molecular markers PTEN and HIF1 alpha correlated with efficacy in patients treated with temsirolimus (Torisel) versus interferon-alpha (IFN). Patients in the IFN group received 3 million U (MU) subcutaneously 3x weekly, escalating to 18 MU....

Reduced-intensity conditioning is effective and safe for transplantation of patients wi...
https://doi.org/10.1038/bmt.2008.151
Bone Marrow Transplantation; Bhatla D, Davies SM et. al.

May 26th, 2008 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative treatment for the BM dysfunction seen in patients with Shwachman-Diamond syndrome (SDS). Historically, these patients have fared poorly with intensive conditioning regimens with increased regimen-related toxicity especially involving the heart and lungs. We report our institutional experience with a reduc...

Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the ...
https://doi.org/10.1002/cncr.28350
Cancer Martin P, Byrtek M et. al.

Sep 5th, 2013 - Drug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were enrolled at academic and community practice sites in the United States between 2004 and 2007. In the curr...

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progres...
https://doi.org/10.1200/JCO.2007.13.6606
Journal of Clinical Oncology : Official Journal of the Am... Ferrandina G, Ludovisi M et. al.

Feb 18th, 2008 - We aimed at investigating the efficacy, tolerability, and quality of life (QOL) of gemcitabine (GEM) compared with pegylated liposomal doxorubicin (PLD) in the salvage treatment of recurrent ovarian cancer. A phase III randomized multicenter trial was planned to compare GEM (1,000 mg/m(2) on days 1, 8, and 15 every 28 days) with PLD (40 mg/m(2) every 28 days) in ovarian cancer patients who expe...

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton my...
https://doi.org/10.1038/clpt.2009.35
Clinical Pharmacology and Therapeutics; Wirtz PW, Verschuuren JJ et. al.

Apr 9th, 2009 - 3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination. 3,4-Diaminopyridine enhances the release of acetylcholine at the neuromuscular synapse, and pyridostigmine inhibits the degradation of this neurotransmitter. Although this could lead to a synergistic effect on neuromuscular transmission, no studies have compa...

Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 12...
https://doi.org/10.1210/jc.2011-2508
The Journal of Clinical Endocrinology and Metabolism; van der Lely AJ, Biller BM et. al.

Feb 29th, 2012 - Pegvisomant is a GH receptor antagonist. The ACROSTUDY is a global safety surveillance study of long-term treatment of acromegaly with pegvisomant. The objective of the study was to monitor long-term safety and treatment outcomes. ACROSTUDY is open to all patients with acromegaly who are treated with pegvisomant. We report an interim analysis of data captured from 1288 subjects enrolled before ...

Hypokalemic paralysis as primary presentation of Fanconi syndrome associated with Sjögr...
https://doi.org/10.1097/RHU.0b013e3181df903f
Journal of Clinical Rheumatology : Practical Reports on R... Wang CC, Shiang JC et. al.

Apr 23rd, 2010 - Hypokalemic paralysis is a rare presentation of Fanconi syndrome (FS) caused by Sjögren Syndrome (SS). We describe a 39-year-old man who manifested flaccid paralysis of 4 limbs. Laboratory investigations showed profound hypokalemia (1.6 mmol/L) with renal K wasting, hyperchloremic metabolic acidosis with positive urine anion gap, hypophosphatemia with hyperphosphaturia, hypouricemia with hyperu...

Single-centre prospective comparison between contrast-enhanced ultrasound and computed ...
https://doi.org/10.1016/j.ejvs.2011.09.003
European Journal of Vascular and endoVascular Surgery : T... Perini P, Sediri I et. al.

Oct 3rd, 2011 - To evaluate contrast-enhanced ultrasound (CEUS) as an effective alternative to CT-angiography (CTA) for endoleak detection and aneurismal sac diameter measurement in the follow-up after endovascular abdominal aortic aneurysm repair (EVAR). From January 2006 to December 2010, 395 patients underwent EVAR follow-up with both CTA and CEUS. The diameter of the aneurismal sac and the presence of endo...

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa...
https://doi.org/10.1200/JCO.2008.19.3342
Journal of Clinical Oncology : Official Journal of the Am... Escudier B, Szczylik C et. al.

Jan 27th, 2009 - An open-label, phase II study to evaluate progression-free survival (PFS), overall best response, adverse events (AEs), and patient-reported outcomes with sorafenib versus interferon alfa-2a (IFN-alpha-2a) in patients with untreated, advanced renal cancer. A total of 189 patients were randomly assigned to oral sorafenib 400 mg twice daily or to subcutaneous IFN-alpha-2a 9 million U three times ...

Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724181
Neuro-oncology Rudà R, Bosa C et. al.

Sep 1st, 2015 - Few data are available on temozolomide (TMZ) in ependymomas.We investigated the response, survival, and correlation with MGMT promoter methylation in a cohort of patients with adult intracranial ependymoma receiving TMZ as salvage therapy after failure of surgery and radiotherapy. We retrieved clinical information from the institutional database and follow-up visits, and response to TMZ on MRI ...